טוען...
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications fo...
שמור ב:
| הוצא לאור ב: | Blood Lymphat Cancer |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6910100/ https://ncbi.nlm.nih.gov/pubmed/31849558 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S231821 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|